<?xml version="1.0" encoding="iso-8859-1"?>
<rss version="2.0">
<channel>
<title>Latest Medical Technology from Bio-Medicine.Org</title>
<link>http://www.bio-medicine.org/medicine-technology-1/</link>
<description>Latest Medical Technology lists</description>
<language>en-us</language>
<copyright>Copyright 2007. Bio-Medicine All Rights Reserved.</copyright>
<item>
<title><![CDATA[White Nose Syndrome: Is Pennsylvania Next?]]></title>
<link>http://www.bio-medicine.org/medicine-technology-1/White-Nose-Syndrome-3A-Is-Pennsylvania-Next-3F-2029-1/</link>
<pubDate>Fri, 09 May 2008 07:20:16 MST</pubDate>
<description><![CDATA[Agency biologists will play key role in national effort probing for answers     By Joe Kosack   Wildlife Conservation Education Specialist   Pennsylvania Game Commission     NOTE: Photos to accompany the following article are available from the Game Commission's website  (http://www.pgc.state.pa.us ) by clicking on "Release #049-08."     HARRISBURG, Pa., May 7 /PRNewswire-USNewswire/ -- The... ]]></description>
</item>
<item>
<title><![CDATA[Animals That Cyclone Survivors Depend on Need Help Now]]></title>
<link>http://www.bio-medicine.org/medicine-technology-1/Animals-That-Cyclone-Survivors-Depend-on-Need-Help-Now-2028-1/</link>
<pubDate>Fri, 09 May 2008 07:20:03 MST</pubDate>
<description><![CDATA[BANGKOK, Thailand, May 9 /PRNewswire-USNewswire/ -- An emergency veterinary team from the World Society for the Protection of Animals (WSPA) is on stand-by in Thailand awaiting authority to enter cyclone struck Myanmar to assess and then relieve the suffering of thousands of animals that human survivors depend on for food and their livelihoods.     WSPA is receiving daily updates from The Fo... ]]></description>
</item>
<item>
<title><![CDATA[Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile]]></title>
<link>http://www.bio-medicine.org/medicine-technology-1/Results-of-Phase-3-Study-Show-Tapentadol-IR-Relieves-Acute-Pain-and-Offers-Favorable-Gastrointestinal-Tolerability-Profile-2027-1/</link>
<pubDate>Fri, 09 May 2008 01:35:48 MST</pubDate>
<description><![CDATA[TAMPA, Fla., May 9 /PRNewswire-USNewswire/ -- Osteoarthritis is a painful and potentially debilitating condition that affects almost 50 million people in the United States. It is caused by deterioration of cartilage in bone joints. The novel investigational pain medication tapentadol, a centrally acting oral analgesic, provided significant relief for patients with joint-disease pain, compared... ]]></description>
</item>
<item>
<title><![CDATA[New Study Suggests Tapentadol IR for Acute Pain Is Associated With Improved Gastrointestinal Tolerability Compared to Oxycodone IR]]></title>
<link>http://www.bio-medicine.org/medicine-technology-1/New-Study-Suggests-Tapentadol-IR-for-Acute-Pain-Is-Associated-With-Improved-Gastrointestinal-Tolerability-Compared-to-Oxycodone-IR-2026-1/</link>
<pubDate>Fri, 09 May 2008 01:35:38 MST</pubDate>
<description><![CDATA[TAMPA, Fla., May 9 /PRNewswire-USNewswire/ -- Many strong acting pain medications have bothersome side effects. These can include nausea and vomiting with short-term use, and constipation with longer, chronic use. Such symptoms can lead patients to discontinue treatment, adding additional complications to pain management for physicians. The novel investigational medication tapentadol, a cent... ]]></description>
</item>
<item>
<title><![CDATA[New Data From Phase 3 Study Suggests Tapentadol Immediate Release Effective for Acute Pain From Common Foot Surgery]]></title>
<link>http://www.bio-medicine.org/medicine-technology-1/New-Data-From-Phase-3-Study-Suggests-Tapentadol-Immediate-Release-Effective-for-Acute-Pain-From-Common-Foot-Surgery-2025-1/</link>
<pubDate>Fri, 09 May 2008 01:35:27 MST</pubDate>
<description><![CDATA[Novel Pain Medicine Studied in Patients Following Bunionectomy       TAMPA, Fla., May 9 /PRNewswire-USNewswire/ -- Many foot-surgery patients experience intense pain for several days following removal of a bunion, one of the most common foot surgeries. The investigational pain medication tapentadol provided significant relief for patients who had this surgery, compared to those treated with... ]]></description>
</item>
<item>
<title><![CDATA[Preventing Prostate Cancer and BPH: Prostate-Health Expert Available (National Men's Health Week Is June 9-15)]]></title>
<link>http://www.bio-medicine.org/medicine-technology-1/Preventing-Prostate-Cancer-and-BPH-3A-Prostate-Health-Expert-Available--28National-Mens-Health-Week-Is-June-9-15-29-2024-1/</link>
<pubDate>Fri, 09 May 2008 12:22:20 MST</pubDate>
<description><![CDATA[SEATTLE, May 9 /PRNewswire-USNewswire/ -- The risk of the two major prostate diseases, cancer and benign prostatic hyperplasia (BPH), can be reduced by changes in lifestyle, such as avoiding smoking, maintaining a normal weight and eating a healthy diet. Alan Kristal, Dr.P.H., associate head of the Cancer Prevention Program at Fred Hutchinson Cancer Research Center in Seattle, has conducted... ]]></description>
</item>
<item>
<title><![CDATA[Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results]]></title>
<link>http://www.bio-medicine.org/medicine-technology-1/Ardea-Biosciences-Appoints-John-W--Beck-Chief-Financial-Officer--Announces-Clinical-Development-Progress-and-Reports-First-Quarter-2008-Financial-Resu-2023-1/</link>
<pubDate>Fri, 09 May 2008 06:02:40 MST</pubDate>
<description><![CDATA[SAN DIEGO, May 9 /- Ardea Biosciences, Inc. (Nasdaq:  RDEA ), a company focused on the discovery and development of small- molecule therapeutics for the treatment of HIV, cancer and inflammatory diseases, including gout, today announced that John W. Beck has been appointed Senior Vice President, Finance and Operations and Chief Financial Officer effective May 27, 2008.... ]]></description>
</item>
<item>
<title><![CDATA[Cytopia Announces Novel Anti-Cancer Drug Development Collaboration]]></title>
<link>http://www.bio-medicine.org/medicine-technology-1/Cytopia-Announces-Novel-Anti-Cancer-Drug-Development-Collaboration-2022-1/</link>
<pubDate>Fri, 09 May 2008 12:00:47 MST</pubDate>
<description><![CDATA[Boosts Cytopia's development of early pipeline cancer drug candidates   MELBOURNE, Australia, May 9 /- Cytopia Limited (ASX: CYT) today announced that it has entered into an anti-cancer drug discovery and development collaboration with Cancer Therapeutics CRC Pty Ltd. This agreement leverages Cytopia's early stage drug discovery pipeline of kinase inhibitors, a class of... ]]></description>
</item>
<item>
<title><![CDATA[New Study Demonstrates ACTEMRA(R) (tocilizumab) Inhibits Progression of Joint Damage in Rheumatoid Arthritis Patients]]></title>
<link>http://www.bio-medicine.org/medicine-technology-1/New-Study-Demonstrates-ACTEMRA-28R-29--28tocilizumab-29-Inhibits-Progression-of-Joint-Damage-in-Rheumatoid-Arthritis-Patients-2021-1/</link>
<pubDate>Fri, 09 May 2008 12:00:41 MST</pubDate>
<description><![CDATA[- Fifth International Phase III Study Shows Positive Results with X-ray                                 Data -   NUTLEY, N.J., May 9 /- Roche today announced one-year results from a new two-year Phase III study showing that ACTEMRA(TM) (tocilizumab) can significantly inhibit progression of structural damage to joints in patients with rheumatoid arthritis (RA), a critical measure o... ]]></description>
</item>
<item>
<title><![CDATA[DaVita Clinical Research Completes Record Number of Renal Trials in 2007]]></title>
<link>http://www.bio-medicine.org/medicine-technology-1/DaVita-Clinical-Research-Completes-Record-Number-of-Renal-Trials-in-2007-2020-1/</link>
<pubDate>Thu, 08 May 2008 07:33:17 MST</pubDate>
<description><![CDATA[Nation's Largest Renal Research Network Completes 13 Phase-I Clinical   Trials; Reports Another 34 Active Trials in Late Stage Development   EL SEGUNDO, Calif., May 8 /- DaVita Clinical Research(R) (DCR), a Phase I-IV clinical trial research service business specializing in renal-related drug and device research and development for FDA approval, reports it completed 13 Phase-I cl... ]]></description>
</item>
<item>
<title><![CDATA[DATATRAK International Reports First Quarter Results for 2008]]></title>
<link>http://www.bio-medicine.org/medicine-technology-1/DATATRAK-International-Reports-First-Quarter-Results-for-2008-2019-1/</link>
<pubDate>Thu, 08 May 2008 02:08:34 MST</pubDate>
<description><![CDATA[CLEVELAND, May 8 /- DATATRAK International, Inc. (Nasdaq:  DATA ), a technology and services company focused on global eClinical solutions for the clinical trials industry, today reported its operating results for the first quarter of 2008.   For the three months ended March 31, 2008, revenue decreased approximately 41% to $2,088,000 and the Company reported a net loss... ]]></description>
</item>
<item>
<title><![CDATA[Globus Medical Completes Enrollment Of SECURE(R)-C Cervical Artificial Disc Clinical Trial]]></title>
<link>http://www.bio-medicine.org/medicine-technology-1/Globus-Medical-Completes-Enrollment-Of-SECURE-28R-29-C-Cervical-Artificial-Disc-Clinical-Trial-2018-1/</link>
<pubDate>Thu, 08 May 2008 01:12:27 MST</pubDate>
<description><![CDATA[MIAMI, May 8 /- Globus Medical, Inc., the largest privately held spinal implant manufacturer in the world and a recognized leader in motion preservation technology, today announced the completion of enrollment in its SECURE(R)-C Cervical Artificial Disc IDE study. The SECURE(R)-C device is designed to mimic the normal motion of the spine in order to alleviate pain and restore fu... ]]></description>
</item>
<item>
<title><![CDATA[World Renowned Cancer Centers Implore Americans to Donate $1 to Make Change and Accelerate Cancer Research]]></title>
<link>http://www.bio-medicine.org/medicine-technology-1/World-Renowned-Cancer-Centers-Implore-Americans-to-Donate--241-to-Make-Change-and-Accelerate-Cancer-Research-2017-1/</link>
<pubDate>Thu, 08 May 2008 12:17:20 MST</pubDate>
<description><![CDATA[BOSTON, May 8 /- The Cancer Research Alliance, an organization comprised of 12 of the nation's top cancer centers, is asking 303 million Americans to exercise their power over cancer by donating $1 to cancer research efforts this Mother's Day through Father's Day.   The campaign, dubbed the "Infinite Power of One(TM)" has two key goals: to activate Americans everywhere to take m... ]]></description>
</item>
<item>
<title><![CDATA[Results of the Phase III Pivotal Study of VYVANSE(TM) (Lisdexamfetamine Dimesylate) for the Treatment of ADHD in Adults Presented at National Scientific Meeting of Psychiatrists]]></title>
<link>http://www.bio-medicine.org/medicine-technology-1/Results-of-the-Phase-III-Pivotal-Study-of-VYVANSE-28TM-29--28Lisdexamfetamine-Dimesylate-29-for-the-Treatment-of-ADHD-in-Adults-Presented-at-National--2016-1/</link>
<pubDate>Thu, 08 May 2008 09:10:23 MST</pubDate>
<description><![CDATA[VYVANSE demonstrated significant improvement in ADHD symptoms in adults   WASHINGTON, May 8 /- Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, today presented the results of a phase III pivotal study in which VYVANSE demonstrated significant improvements in Attention Deficit Hyperactivity Disorder (ADHD) symptoms in adults and met all... ]]></description>
</item>
<item>
<title><![CDATA[Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting]]></title>
<link>http://www.bio-medicine.org/medicine-technology-1/Overview-of-Asenapine-Data-from-Olympia-Trial-Program-Presented-at-American-Psychiatric-Association-Annual-Meeting-2015-1/</link>
<pubDate>Thu, 08 May 2008 09:10:11 MST</pubDate>
<description><![CDATA[Efficacy and safety data support potential of asenapine in the treatment of                  schizophrenia and bipolar I disorder   WASHINGTON, May 8 /- Schering-Plough Corporation (NYSE:  SGP ) today announced that an overview of asenapine clinical trials from the Olympia program was presented at the 161st Annual Meeting of the American Psychiatric Association in Washingt... ]]></description>
</item>
<item>
<title><![CDATA[Alpharma Presents Data Addressing Abuse Liability Features, Safety and Efficacy on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) at the American Pain Society Annual Scientific Session]]></title>
<link>http://www.bio-medicine.org/medicine-technology-1/Alpharma-Presents-Data-Addressing-Abuse-Liability-Features--Safety-and-Efficacy-on-ALO-01--28EMBEDA-28TM-29-29--28morphine-sulfate-extended-release-wi-2014-1/</link>
<pubDate>Thu, 08 May 2008 08:05:28 MST</pubDate>
<description><![CDATA[TAMPA, Fla., May 8 /- Alpharma Inc. (NYSE:  ALO ), a global specialty pharmaceutical company, today announced results from clinical trials that showed ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) capsules demonstrated clinically relevant features addressing abuse liability alongside a promising safety and efficacy pr... ]]></description>
</item>
<item>
<title><![CDATA[Siemens and LabCorp Enter Agreement to Co-Develop New Clinical Diagnostic Tests]]></title>
<link>http://www.bio-medicine.org/medicine-technology-1/Siemens-and-LabCorp-Enter-Agreement-to-Co-Develop-New-Clinical-Diagnostic-Tests-2013-1/</link>
<pubDate>Thu, 08 May 2008 07:09:15 MST</pubDate>
<description><![CDATA[DEERFIELD, Ill., May 8 /- Siemens Healthcare and Laboratory Corporation of America(R) Holdings (LabCorp(R)) today announced that they have entered a non-exclusive agreement to discuss future possibilities to co-develop new clinical diagnostic tests in the areas of companion diagnostics, metabolic syndrome, oncology and diabetes. Under the agreement, initial discussions... ]]></description>
</item>
<item>
<title><![CDATA[Skin Flaps Deliver Cancer-fighting Therapy, ASPS Study Reveals]]></title>
<link>http://www.bio-medicine.org/medicine-technology-1/Skin-Flaps-Deliver-Cancer-fighting-Therapy--ASPS-Study-Reveals-2012-1/</link>
<pubDate>Thu, 08 May 2008 07:09:07 MST</pubDate>
<description><![CDATA[Treatment Provides "Blueprint" to Produce Therapeutic Proteins at Tumor Site     ARLINGTON HEIGHTS, Ill., May 8 /PRNewswire-USNewswire/ -- Using gene therapy, plastic surgeons have delivered cancer fighting proteins through skin flaps placed on cancerous tumors on rats with a 79 percent reduction in tumor volume, according to a study in the May issue of Plastic and Reconstructive Surgery(R),... ]]></description>
</item>
<item>
<title><![CDATA[Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Cytarabine]]></title>
<link>http://www.bio-medicine.org/medicine-technology-1/Vion-Pharmaceuticals-Announces-Initiation-of-Clinical-Trial-of-Cloretazine-28R-29--28VNP40101M-29-in-Combination-with-Cytarabine-2011-1/</link>
<pubDate>Thu, 08 May 2008 06:16:55 MST</pubDate>
<description><![CDATA[NEW HAVEN, Conn., May 8 /- VION PHARMACEUTICALS, INC. (Nasdaq:  VION ) today announced the start of an investigator-sponsored Phase I/II clinical trial of its lead anticancer agent Cloretazine(R) (VNP40101M) in combination with cytarabine in elderly patients with previously untreated acute myelogenous leukemia (AML) and high-risk myelodysplastic syndromes (MDS). The tr... ]]></description>
</item>
<item>
<title><![CDATA[New Lacosamide Data Provides Evidence for Long-Term Efficacy in Diabetic Neuropathic Pain]]></title>
<link>http://www.bio-medicine.org/medicine-technology-1/New-Lacosamide-Data-Provides-Evidence-for-Long-Term-Efficacy-in-Diabetic-Neuropathic-Pain-2010-1/</link>
<pubDate>Thu, 08 May 2008 06:16:47 MST</pubDate>
<description><![CDATA[Results presented at the 27th Annual Meeting of the American Pain Society                                 (APS)   SMYRNA, Ga., May 8 /- Patients treated with lacosamide demonstrated sustained pain relief from diabetic neuropathic pain (DNP), compared to placebo-treated patients, according to data presented at the 27th annual meeting of the American Pain Society (APS) in Tampa, Fla.... ]]></description>
</item>
</channel>
</rss>